Microsoft Partners With SRL to Expand AI Network to Detect Cancer

Advertisement
By Indo-Asian News Service | Updated: 12 September 2018 16:36 IST
Highlights
  • Collaboration will help improve the quality of digital pathology
  • We are committed to empowering patients: Microsoft
  • Diagnosis is the first step to disease management: SRL

After training its artificial intelligence (AI) system for eyecare and cardiology, Microsoft India on Tuesday announced their partnership with SRL Diagnostics to expand the "AI Network for Healthcare" to pathology to detect cancer.

The collaboration will help improve the quality of digital pathology for population screening by bringing together Microsoft's Azure and AI innovations along with SRL's expertise in the study of cells and tissues (histology).

"Microsoft is committed to empower both the healthcare industry and patients by using AI to democratise healthcare for all. Our partnership with SRL Diagnostics will assist pathologists by equipping them with technology that will augment their capability," Anil Bhansali, Managing Director, Microsoft India (R&D), said in a statement.

Advertisement

As part of the partnership, Microsoft will build an AI platform to create a software environment using SRL's repository of more than a million histopathology slides.

Advertisement

By increasing efficiency in the initial steps in a biopsy tissue analysis through artificial neural networks, it will be possible for a histopathology laboratory to cut down on inadvertent manual errors and process more samples in a day with higher level of accuracy.

"Diagnosis is the first step to disease management. Without accurate identification of the cause, there is no possibility of a precise treatment. With the growing number of samples of cancer, as well as of other diseases, there's a need to quickly and accurately analyse the samples to help doctors arrive at a diagnosis faster," said Arindam Haldar, Chief Executive Officer at SRL Diagnostics.

Advertisement

The "AI Network for Healthcare" aims to maximise the ability of AI and cloud computing to accelerate innovation in the healthcare industry and improve the lives of people around the world.

Earlier, Microsoft had applied AI to devices for early detection of diabetic retinopathy to prevent blindness and an AI-powered Cardiovascular Disease Risk Score API (Application programme interface).

Advertisement

This is the third area where Microsoft has expanded the AI Network for Healthcare, Bhansali said. "We will continue to look for other areas where we can deploy technology to make healthcare more accessible."

 

Get your daily dose of tech news, reviews, and insights, in under 80 characters on Gadgets 360 Turbo. Connect with fellow tech lovers on our Forum. Follow us on X, Facebook, WhatsApp, Threads and Google News for instant updates. Catch all the action on our YouTube channel.

Further reading: Microsoft, AI, SRL Diagnostics
Advertisement

Related Stories

Popular Mobile Brands
  1. Nothing's First India Flagship Store Opens in Bengaluru
  1. NASA Juno Mission Uncovers Subtle Geometric Shifts That Challenge Existing Models of the Jovian Interior
  2. The Conjuring: Last Rites Now Streaming on JioHotstar: When, Where to Watch the Warrens’ Final Case Online?
  3. Google Rolls Out First Android 17 Beta Update With Performance Optimisation Tools: Features, Compatible Models
  4. iPhone 18 Pro, iPhone 18 Pro Max to Feature A20 Pro Chip, Smaller Dynamic Island and More: Report
  5. First Look: Nothing’s First India Flagship Store Opens in Bengaluru
  6. The Housemaid Now Streaming Online: All You Need to Know About the Sydney Sweeney Thriller
  7. Astronomers Witness Rare Failed Supernova in Andromeda Galaxy
  8. Unique Inside-Out Planetary System Reveals Unexpected Rocky World on the Outer Edge
  9. Google Chrome Brings Convenient Pinned Tabs Feature to Android Smartphone Owners
  10. Poco C81 Pro Appears on Thailand's NBTC Certification Database, Might Launch Soon
Gadgets 360 is available in
Download Our Apps
Available in Hindi
© Copyright Red Pixels Ventures Limited 2026. All rights reserved.